HDAC inhibitors (HDACi), a unique class of epigenetic modifiers, have gained prominence in the laboratory and as therapeutic agents (Table 3) for a variety of pathologies, especially cancer [122,123,124] and autoimmune diseases [125]. The gene discussed is HDAC9; the disease is cancer.